Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 0.13%, near the low end of its 5-year range (0.00%–71.37%).
As of the fiscal period ended Tuesday, June 30, 2026. 100.00% below its 12-month average of 35.12%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
35.12%
DEBT TO ASSETS RATIO AVG 3Y
16.12%
DEBT TO ASSETS RATIO AVG 5Y
0.13%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 847 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
CalciMedica, Inc.
Market Cap
$4.63M
Debt to Assets Ratio
0.00%
TTM Avg
35.12%
3Y Avg
16.12%
5Y Avg
0.13%
Market Cap
$4.61M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.69M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.51M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.83M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.34M
Debt to Assets Ratio
0.37%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.94M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.00M
Debt to Assets Ratio
0.42%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CalciMedica, Inc. (CALC) | $4.63M | 0.00% | 35.12% | 16.12% | 0.13% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.61M | 0.00% | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.69M | 0.00% | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.51M | 0.00% | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.83M | 0.00% | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | 0.37% | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.94M | 0.02% | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.96M | 0.52% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | 0.42% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | 0.49% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
5.58
Interest Coverage
-16.3x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 71.37% |
| 2025-09-30 | 59.68% |
| 2025-06-30 | 44.55% |
| 2025-03-31 | 33.93% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.67% |
| 2022-06-30 | 0.74% |
| 2022-03-31 | 0.81% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-12-31 | 0.00% |
